Todesco Eve, Mazzola Alessandra, Akhavan Sepideh, Abravanel Florence, Poynard Thierry, Roque-Afonso Anne-Marie, Peytavin Gilles, Marcelin Anne-Geneviève, Calmus Yvon, Lecuyer Lucien, Guillemain Romain, Conti Filomena
Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Department of Virology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Antivir Ther. 2018;23(5):463-465. doi: 10.3851/IMP3227.
Hepatitis E virus (HEV) can induce chronic infections in the case of immunosuppression, which are sometimes not cured with ribavirin. Furthermore, sofosbuvir is a highly potent inhibitor of HCV polymerase and was shown to inhibit HEV genotype-3 replication in vitro. We report here the outcome of sofosbuvir/ribavirin therapy on a chronic HEV infection in a heart transplant recipient non-responder to ribavirin. After 24 weeks, the regimen failed to cure the persistent HEV infection, highlighting the need of therapeutic options for HEV-infected immunosuppressed patients.
戊型肝炎病毒（HEV）在免疫抑制情况下可引发慢性感染，有时使用利巴韦林无法治愈。此外，索磷布韦是一种高效的丙型肝炎病毒聚合酶抑制剂，已证实在体外可抑制HEV 3型复制。我们在此报告索磷布韦/利巴韦林疗法对一名心脏移植受者慢性HEV感染（对利巴韦林无反应）的治疗结果。24周后，该治疗方案未能治愈持续性HEV感染，凸显了为HEV感染的免疫抑制患者提供治疗选择的必要性。
Zotero 插件